Unilabs, a provider of diagnostic services, and Ibex Medical Analytics, a specialist in artificial intelligence-powered cancer diagnostics, have signed a deal to implement Ibex’s AI platform in Europe.
Starting with a national roll out in Sweden, Unilabs will then roll the platform out across all of its 16 countries. Unilabs is the first pan-European diagnostics provider to deploy Ibex’s multi-tissue AI-powered Galen platform, aiming to provide patients and physicians with a faster and more accurate diagnosis.
Dr. Christian Rebhan, Unilabs’ chief medical & operations officer, said: “This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes. When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs’ pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe.”
Joseph Mossel, chief executive officer and co-founder of Ibex Medical Analytics, said: “Ibex is transforming cancer with innovative AI solutions across the diagnostic pathway. We are excited to partner with Unilabs to deploy our AI solutions and empower their pathologists with faster turnaround times and quality diagnosis. This cooperation follows a thorough evaluation of our technology at Unilabs, and demonstrates the robustness and utility of our platform for everyday clinical practice."
Using algorithms developed with advanced machine learning, the Galen platform is trained to detect cancer and other clinical findings. The algorithms automatically analyse images from tissue biopsies, providing insights to pathologists who diagnose the case and whose assessment is vital for reaching correct treatment decisions by oncologists. These AI-generated insights include case prioritisation worklists, cancer heatmaps, tumour grading and measurement, streamlined reporting tools and more.
Ibex's Galen platform is CE marked for breast and prostate cancer detection in multiple workflows and was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
